Insmed freezes Brinsupri's HS programme on Phase II failure [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
This follows the results of the Phase IIb CEDAR study (NCT06685835), which revealed that neither a 10mg nor a 40mg dose of Brinsupri bested the baseline reduction in total abscess and inflammatory nodules versus placebo. During the trial, patients given a low or high daily dose of the dipeptidyl peptidase 1 (DDP1) blocker saw a 45.5% and 40.3% drop in abscess and nodule counts from baseline, while the placebo group experienced a 57.1% reduction, missing the trial's primary endpoint. The drug also failed to meet the secondary endpoints, which included measures of clinical response, number of flares, symptomatic severity and quality of life (QoL) measures. Insmed is yet to share data from these elements of the trial, though the company does plan to disclose details at an upcoming medical conference. Patients generally tolerated Brinsupri well in this trial, with one and three individuals (1.4%, 4.1%) experiencing a severe or serious treatment-emergent adverse event (TEAE) in the
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".MarketBeat
- Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.MarketBeat
- Insmed discontinues development of skin condition drug after mid-stage study miss [Yahoo! Finance]Yahoo! Finance
- Insmed Provides Clinical Update on Phase 2b CEDAR StudyPR Newswire
- Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 4/8/26 - Form 4
- 4/7/26 - Form 8-K
- 4/6/26 - Form 144
- INSM's page on the SEC website